AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16397161 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups and semistructured interviews with girls (N = 100) and boys (N = 77)
Number of subjects: 177
Study 16397161 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of TAAG interventions
Number of subjects: 177
Study 15570274 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous radiofrequency obliteration (RFO)
Number of subjects: 45
Study 15570274 — intervention group
Group type: COMPARATOR
Intervention: Ligation and vein stripping (S and L)
Number of subjects: 45
Study 10683000 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) plus vitamin B6 (250 mg) daily for 2 years
Number of subjects: 158
Study 10683000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 10183187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (specific details not available)
Number of subjects: 1278
Study 10183187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (specific details not available)
Number of subjects: 1278
Study 10183187 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not available)
Number of subjects: 1278
Study 8372519 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 24
Study 8372519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold saline organ perfusion
Number of subjects: 24
Study 8372519 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 3528273 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle touch during eating
Number of subjects: 42
Study 3528273 — intervention group
Group type: COMPARATOR
Intervention: Verbal encouragement
Number of subjects: 42
Study 3335080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (VLB) 6 mg/m2 weekly intravenous bolus injection
Number of subjects: 50
Study 3335080 — intervention group
Group type: COMPARATOR
Intervention: Locoregional radiotherapy (RT) alone
Number of subjects: 50
Study 31551155 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT-A (n = 330)
Number of subjects: 661
Study 31551155 — intervention group
Group type: COMPARATOR
Intervention: Morphology alone (n = 331)
Number of subjects: 661
Study 31551155 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT-A in women aged 35-40 years
Number of subjects: 661
Study 28919201 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan (10 mg once a day)
Number of subjects: 80
Study 28919201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28919201 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 80
Study 25976467 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (n-3) supplementation (277.8 mg DHA and 39.0 mg EPA)
Number of subjects: 24
Study 25976467 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (n-3) supplementation
Number of subjects: 24
Study 25976467 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU) treatment (dosage > 20 mg/kg/day)
Number of subjects: 24
Study 25976467 — intervention group
Group type: COMPARATOR
Intervention: n-3 untreated
Number of subjects: 24
Study 23035747 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vaporization
Number of subjects: 65
Study 23035747 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilatation
Number of subjects: 65
Study 21741428 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation (CO(2) laser at 0.3J/cm(2), 0.5μs, 226Hz)
Number of subjects: 60
Study 21741428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride (AmF/NaF gel) application
Number of subjects: 60
Study 21741428 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser prior to fluoride (LF)
Number of subjects: 60
Study 21741428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride prior to laser (FL)
Number of subjects: 60
Study 21741428 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control (C)
Number of subjects: 60
Study 18979086 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-g glucose drink
Number of subjects: 120
Study 18979086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16402081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 363
Study 14580053 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25%
Number of subjects: 60
Study 14580053 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.25%
Number of subjects: 60
Study 11032203 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered communication
Number of subjects: 315
Study 9345021 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (biking on an ergometer in the supine position for 30 minutes daily during hospitalization)
Number of subjects: 33
Study 9345021 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 33
Study 8398218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake (continuous variable)
Number of subjects: 1801
Study 8398218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1801
Study 2427844 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg daily for 2 weeks, then 400 mg daily for 2 weeks, and if necessary 600 mg daily for another 2 weeks.
Number of subjects: 92
Study 2427844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 31852268 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs (biologic disease-modifying anti-rheumatic drugs)
Number of subjects: 0
Study 31852268 — intervention group
Group type: COMPARATOR
Intervention: csDMARDs (conventional synthetic disease-modifying anti-rheumatic drugs)
Number of subjects: 0
Study 31852268 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs (specifically rituximab)
Number of subjects: 0
Study 31852268 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors
Number of subjects: 0
Study 31852268 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine and TNF inhibitors
Number of subjects: 0
Study 31852268 — intervention group
Group type: EXPERIMENTAL
Intervention: rituximab
Number of subjects: 0
Study 27856142 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (15 mg/kg intravenously every 3 weeks) in combination with bevacizumab-based chemotherapy
Number of subjects: 259
Study 27856142 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (15 mg/kg intravenously every 3 weeks) in combination with pemetrexed-based chemotherapy
Number of subjects: 259
Study 27856142 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with bevacizumab-based chemotherapy
Number of subjects: 259
Study 27856142 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with pemetrexed-based chemotherapy
Number of subjects: 259
Study 27856142 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Number of subjects: 259
Study 26214269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 140
Study 24393344 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) in addition to standard wound care (5 sessions per week for 8 weeks)
Number of subjects: 0
Study 24393344 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (5 sessions per week for 8 weeks)
Number of subjects: 0
Study 22366196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg, 400 μg, 800 μg, twice daily for 7 days
Number of subjects: 30
Study 22366196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg, twice daily for 7 days
Number of subjects: 30
Study 22366196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 800 μg, twice daily for 7 days
Number of subjects: 30
Study 22366196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium (all doses), twice daily for 7 days
Number of subjects: 30
Study 18979100 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intra-arterial chemotherapy
Number of subjects: 53
Study 17263651 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) based counseling
Number of subjects: 56
Study 17263651 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 56
Study 14871511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolysis with ritodrine
Number of subjects: 60
Study 14871511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tocolysis)
Number of subjects: 60
Study 11880016 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on the distal end of the endotracheal tubes (ETTs)
Number of subjects: 204
Study 11880016 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on laryngopharyngeal structures
Number of subjects: 204
Study 11880016 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly lubricated on distal ends of ETTs
Number of subjects: 204
Study 11880016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) lidocaine administered at the conclusion of surgery
Number of subjects: 204
Study 11880016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff lidocaine
Number of subjects: 204
Study 11880016 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline lubricated on terminal end of ETTs
Number of subjects: 204
Study 10726810 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7587896 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlutal (group A)
Number of subjects: 60
Study 7587896 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlutal (group B)
Number of subjects: 60
Study 7587896 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlutal (group C)
Number of subjects: 60
Study 7587896 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (control)
Number of subjects: 60
Study 7587896 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Furlutal
Number of subjects: 60
Study 2339013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline + psychotherapy (N = 26), twelve 45 min weekly sessions
Number of subjects: 102
Study 2339013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline + support (N = 26), six 15 min fortnightly sessions
Number of subjects: 102
Study 2339013 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet + psychotherapy (N = 26), twelve 45 min weekly sessions
Number of subjects: 102
Study 2339013 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet + support (N = 24), six 15 min fortnightly sessions
Number of subjects: 102
Study 2339013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline + psychotherapy (N = 26)
Number of subjects: 102
Study 2339013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (general)
Number of subjects: 102
Study 2339013 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (general)
Number of subjects: 102
Study 7006811 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldoretic (methyldopa, hydrochlorothiazide, and amiloride)
Number of subjects: 361
Study 7006811 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide and amiloride
Number of subjects: 361
Study 7006811 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa alone
Number of subjects: 361
Study 31358922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Conbercept injections (three loading doses and thereafter pro re nata [PRN])
Number of subjects: 160
Study 31358922 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 months' sham injection, then one Conbercept injection at month 4 and thereafter PRN)
Number of subjects: 160
Study 31358922 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of MRS
Number of subjects: 160
Study 30712901 — intervention group
Group type: EXPERIMENTAL
Intervention: PICSI
Number of subjects: 2772
Study 30712901 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 2772
Study 28470919 — intervention group
Group type: EXPERIMENTAL
Intervention: Early implantation of veno‐arterial ECMO on the background of standard care
Number of subjects: 120
Study 28470919 — intervention group
Group type: COMPARATOR
Intervention: Early conservative therapy
Number of subjects: 120
Study 27111542 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT for GAD
Number of subjects: 10
Study 27111542 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT for insomnia
Number of subjects: 10
Study 27111542 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT for GAD followed by CBT for insomnia
Number of subjects: 10
Study 27111542 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT for insomnia following CBT for GAD
Number of subjects: 10
Study 24418670 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical read with prior images
Number of subjects: 10
Study 24418670 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory read with prior images
Number of subjects: 10
Study 24418670 — intervention group
Group type: COMPARATOR
Intervention: Laboratory read without prior images
Number of subjects: 10
Study 22528672 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 123
Study 22528672 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 123
Study 19033321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin plus Thymosin alpha(1)
Number of subjects: 56
Study 19033321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17381962 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g carob fibre
Number of subjects: 20
Study 17381962 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g carob fibre
Number of subjects: 20
Study 17381962 — intervention group
Group type: COMPARATOR
Intervention: 0 g carob fibre (control)
Number of subjects: 20
Study 15620164 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol (Propofol‐Lipuro 1%, B. Braun, Melsungen, Germany) in a 10% fat emulsion containing equal proportions (50:50) of medium‐ and long‐chain triglycerides
Number of subjects: 600
Study 11719888 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.075 g x kg(‐1) body mass, 4 times daily for 5 days)
Number of subjects: 9
Study 11719888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrine, 4 times daily for 5 days)
Number of subjects: 9
Study 9533108 — intervention group
Group type: EXPERIMENTAL
Intervention: phenytoin + tirilazad
Number of subjects: 12
Study 7989879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 1: diversified spinal manipulation, drop table adjustments, and cervical extension-compression traction five times per week for 10-14 weeks.
Number of subjects: 95
Study 7989879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 2: diversified spinal manipulation and drop table adjustments five times per week for 10-14 weeks.
Number of subjects: 95
Study 7989879 — intervention group
Group type: COMPARATOR
Intervention: Control group: no health care for 10-14 weeks.
Number of subjects: 95
Study 2465530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg/day)
Number of subjects: 15
Study 2465530 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (800 mg/day)
Number of subjects: 15
Study 2465530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31634011 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enabled clinical trials using electronic health records, mobile applications, and wearable devices
Number of subjects: 0
Study 31634011 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 29102818 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine, 12 weeks of open treatment
Number of subjects: 138
Study 26736632 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min real LTE EMF exposure at 2.573 GHz
Number of subjects: 0
Study 26736632 — intervention group
Group type: COMPARATOR
Intervention: 30 min sham LTE EMF exposure
Number of subjects: 0
Study 23411523 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary protraction with double hinged expander repetitive rapid palatal expansions/constrictions (group B)
Number of subjects: 34
Study 23411523 — intervention group
Group type: COMPARATOR
Intervention: Maxillary protraction with Hyrax expander rapid palatal expansion alone (group A)
Number of subjects: 34
Study 21985070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg day(-1)
Number of subjects: 21
Study 21985070 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg day(-1)
Number of subjects: 21
Study 21985070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 21
Study 21985070 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel
Number of subjects: 21
Study 19834053 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 213
Study 19834053 — intervention group
Group type: COMPARATOR
Intervention: Community Control
Number of subjects: 213
Study 17107539 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo IT motor
Number of subjects: 60
Study 17107539 — intervention group
Group type: COMPARATOR
Intervention: Mtwo direct handpiece
Number of subjects: 60
Study 15515816 — intervention group
Group type: EXPERIMENTAL
Intervention: ccHRT (50 mg of 17beta‐estradiol and 5 mg of oral progesterone)
Number of subjects: 34
Study 15515816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ccHRT)
Number of subjects: 34
Study 15515816 — intervention group
Group type: EXPERIMENTAL
Intervention: ccHRT
Number of subjects: 34
Study 11273923 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 10 mg/kg
Number of subjects: 80
Study 11273923 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 20 mg/kg
Number of subjects: 80
Study 11273923 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 40 mg/kg
Number of subjects: 80
Study 11273923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11273923 — intervention group
Group type: EXPERIMENTAL
Intervention: IV opioid boluses (piritramide)
Number of subjects: 80
Study 9058127 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (laparoscopic colectomy)
Number of subjects: 90
Study 9058127 — intervention group
Group type: COMPARATOR
Intervention: Advanced colorectal cancer treatment
Number of subjects: 90
Study 9058127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastasis in early colorectal cancer
Number of subjects: 90
Study 9058127 — intervention group
Group type: COMPARATOR
Intervention: Comparison of clinicopathologic features
Number of subjects: 90
Study 7643049 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of simple quadratic surfaces with 4-6 points
Number of subjects: 0
Study 7643049 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of hyperbolic shapes
Number of subjects: 0
Study 7643049 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of sinusoidal shapes
Number of subjects: 0
Study 2495913 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human tissue‐type plasminogen activator (rtPA)
Number of subjects: 0
Study 645630 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (4.3, 98.0, and 0.0 mEq/liter of potassium) given 1 to 2 hr before physical activity
Number of subjects: 5
Study 645630 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (98.0 mEq/liter)
Number of subjects: 5
Study 645630 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body potassium measurement before and after exercise
Number of subjects: 5
Study 30658660 — intervention group
Group type: EXPERIMENTAL
Intervention: BMF (Chinese herbal medicine bi min fang)
Number of subjects: 80
Study 30658660 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine hydrochloride (control)
Number of subjects: 80
Study 28216328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5α‐reductase inhibitors
Number of subjects: 78815
Study 28216328 — intervention group
Group type: COMPARATOR
Intervention: Screening
Number of subjects: 78815
Study 28216328 — intervention group
Group type: COMPARATOR
Intervention: Prostate specific antigen and age
Number of subjects: 78815
Study 27618925 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of penicillin V four times daily for 5 days
Number of subjects: 432
Study 27618925 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg of penicillin V three times daily for 10 days
Number of subjects: 432
Study 23820706 — intervention group
Group type: EXPERIMENTAL
Intervention: Large particle size of anorganic bovine bone matrix (ABBM)
Number of subjects: 13
Study 23820706 — intervention group
Group type: COMPARATOR
Intervention: Small particle size of anorganic bovine bone matrix (ABBM)
Number of subjects: 13
Study 22262336 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfixation screw (tricortical or quadricortical syndesmotic screw)
Number of subjects: 30
Study 22262336 — intervention group
Group type: EXPERIMENTAL
Intervention: Reabsorbable cerclage (tibiofibular cerclage with reabsorbing wires)
Number of subjects: 30
Study 19835718 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg/ethinyl estradiol 20 mcg (drsp 3 mg/EE 20 mcg)
Number of subjects: 453
Study 19835718 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel 150 mcg/ethinyl estradiol 20 mcg (DSG 150 mcg/EE 20 mcg)
Number of subjects: 453
Study 16711173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained silver-releasing foam dressing Contreet Foam (ColoplastA/S)
Number of subjects: 619
Study 16711173 — intervention group
Group type: COMPARATOR
Intervention: Local best practice (LBP)
Number of subjects: 619
Study 14998051 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental power toothbrush (twice a day brushing with Crest Cavity Protection dentifrice for 2 minutes each time)
Number of subjects: 27
Study 14998051 — intervention group
Group type: COMPARATOR
Intervention: Peroxide paint-on gel control (Colgate Simply White Night applied once a day for the first 14 days, plus brushing twice a day with Crest Cavity Protection dentifrice for 2 minutes using ADA manual reference toothbrush)
Number of subjects: 27
Study 14998051 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental power toothbrush (in induced stain study)
Number of subjects: 27
Study 11708574 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/day
Number of subjects: 89